Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Spherix Global Insights
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
July 24, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
July 24, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
July 18, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments
July 08, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
June 27, 2024
From
Spherix Global Insights
Via
GlobeNewswire
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
June 26, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
June 24, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer
June 17, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
June 13, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
June 13, 2024
From
Spherix Global Insights
Via
GlobeNewswire
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
June 12, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
June 10, 2024
From
Spherix Global Insights
Via
GlobeNewswire
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
May 09, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
May 01, 2024
From
Spherix Global Insights
Via
GlobeNewswire
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
April 30, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16, 2024
From
Spherix Global Insights
Via
GlobeNewswire
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
April 05, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024
From
Spherix Global Insights
Via
GlobeNewswire
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
March 19, 2024
From
Spherix Global Insights
Via
GlobeNewswire
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
March 14, 2024
From
Spherix Global Insights
Via
GlobeNewswire
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
March 12, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
February 23, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
February 22, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
February 16, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
February 08, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
January 22, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
January 18, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
January 10, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024
From
Spherix Global Insights
Via
GlobeNewswire
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024
From
Spherix Global Insights
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.